Molecular recognition of ITIM/ITSM domains with SHP2 and their allosteric effect-Reference-Cited by-全球学者库

Molecular recognition of ITIM/ITSM domains with SHP2 and their allosteric effect

Published:2024 Issue: Volume: Page:
ISSN:1463-9076
Container-title:Physical Chemistry Chemical Physics
language:en
Short-container-title:Phys. Chem. Chem. Phys.

Author:

Cheng Yan¹²^ORCID,Ouyang Weiwei³,Liu Ling⁴,Tang Lingkai⁴^ORCID,Zhang Zhigang⁴,Yue Xinru⁴,Liang Li⁴,Hu Jianping⁴^ORCID,Luo Ting¹²^ORCID

Affiliation:

1. Breast Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, China

2. Multi-omics Laboratory of Breast Diseases, State Key Laboratory of Biotherapy, National Collaborative, Innovation Center for Biotherapy, West China Hospital, Sichuan University, China

3. Department of Thoracic Oncology, Affiliated Cancer Hospital, Guizhou Medical University, Guiyang, China

4. Key Laboratory of Medicinal and Edible Plants Resources, Development of Sichuan Education Department, School of Pharmacy, Chengdu University, Chengdu, China

Abstract

Src homology 2-domain-containing tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase that is widely expressed in a variety of cells and regulates the immune response of T cells through the PD-1 pathway.

Funder

National Natural Science Foundation of China

Sichuan Province Science and Technology Support Program

Publisher

Royal Society of Chemistry (RSC)

Subject

Physical and Theoretical Chemistry,General Physics and Astronomy

Link

http://pubs.rsc.org/en/content/articlepdf/2024/CP/D3CP03923D

Reference83 articles.

1. Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis.

2. Protein Kinases and Phosphatases in the Control of Cell Fate

3. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase

4. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials

5. SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer